AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jan 14, 2020 at 12:12 AM.

  1. #1 cafead, Jan 14, 2020 at 12:12 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,013
    Likes Received:
    3
    via AstraZeneca and Merck are racing against GlaxoSmithKline to snag an expanded nod for Lynparza in ovarian cancer patients who responded to their first round of chemo. And with a priority nod from the FDA, the partners just got a boost that could put them ahead.

    article source
     
    Quote

Reply to Thread